Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management

Thrombosis Journal

Martin Feuring³  Andreas Clemens²  Adrian E Harrington¹  Jayne Pooley¹  Bastian Hass⁴ 

[1] United BioSource Corporation, River House, 33 Point Pleasant, London, SW18 1NN, UK;Center of Thrombosis and Hemostasis, Johannes Gutenberg University, Medical Center, Mainz, Germany;Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, 55216, Ingelheim am Rhein, Germany;Boehringer Ingelheim GmbH, Binger Strasse 173, 55216, Ingelheim am Rhein, Germany

关键词: Bleeding;    Recurrence;    Heparin;    Vitamin K antagonists;    Anticoagulants;    Venous thromboembolism;   

Others  :  838769
DOI  :  10.1186/1477-9560-10-24

 received in 2012-07-05, accepted in 2012-12-19,  发布年份 2012

【 摘 要 】

Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and bleeding complications. The current standard of care is heparin followed by a vitamin K antagonist such as warfarin. However, this option is not without its limitations, as the anticoagulant effect of warfarin is associated with high inter- and intra-patient variability and patients must be regularly monitored to ensure that anticoagulation is within the narrow target therapeutic range. Several novel oral anticoagulant agents are in the advanced stages of development for VTE treatment, some of which are given after an initial period of heparin treatment, in line with current practice, while others switch from high to low doses after the initial phase of treatment. In this review we assess the critical considerations for treating VTE in light of emerging clinical data for new oral agents and discuss the merits of novel treatment regimens for patients who have experienced an episode of deep vein thrombosis or pulmonary embolism.

【 授权许可】

   
2012 Hass et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ: Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:454S-545S.
• [2]Stein PD, Hull RD, Matta F, Yaekoub AY: Anticoagulant therapy for acute venous thromboembolism: what we think we know and what the data show for the timing of recurrent events. Clin Appl Thromb Hemost 2009, 15:609-612.
• [3]Hansson PO, Sorbo J, Eriksson H: Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000, 160:769-774.
• [4]Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ: III: Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000, 160:761-768.
• [5]Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, et al.: The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997, 82:423-428.
• [6]Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS: Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000, 160:3431-3436.
• [7]van Dongen CJ, Vink R, Hutten BA, Buller HR, Prins MH: The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med 2003, 163:1285-1293.
• [8]Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, et al.: Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. Br Med J 2012, 342:d813.
• [9]Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS: Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998, 279:458-462.
• [10]Spencer FA, Gore JM, Lessard D, Douketis JD, Emery C, Goldberg RJ: Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med 2008, 168:425-430.
• [11]Murin S, Romano PS, White RH: Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002, 88:407-414.
• [12]Kearon C: Natural history of venous thromboembolism. Circulation 2003, 107:I22-I30.
• [13]Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
• [14]Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A: Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005, 294:706-715.
• [15]Schulman S, Beyth RJ, Kearon C, Levine MN: Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:257S-298S.
• [16]Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al.: A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999, 340:901-907.
• [17]Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al.: The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997, 336:393-398.
• [18]Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al.: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
• [19]Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al.: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
• [20]Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al.: Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005, 293:681-689.
• [21]Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al.: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
• [22]Schulman S, Kakkar AK, Schellong SM, Goldhaber SZ, Henry E, Mismetti P, et al.: A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). American Society of Hematology Annual Meeting; [https://ash.confex.com/ash/2011/webprogram/Paper42341.html webcite] Accessed October 22, 2012
• [23]Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
• [24]Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
• [25]Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
• [26]Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, et al.: Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006, 296:935-942.
• [27]Prandoni P, Carnovali M, Marchiori A: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004, 164:1077-1083.
• [28]Cappelleri JC, Fiore LD, Brophy MT, Deykin D, Lau J: Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a metaanalysis. Am Heart J 1995, 130:547-552.
• [29]Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD: Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester. Minnesota. Mayo Clin Proc 1995, 70:725-733.
• [30]Linkins LA, Choi PT, Douketis JD: Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003, 139:893-900.
• [31]Spencer FA, Gore JM, Reed G, Lessard D, Pacifico L, Emery C, et al.: Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. Thromb Haemost 2009, 101:878-885.
• [32]Carrier M, Le GG, Wells PS, Rodger MA: Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010, 152:578-589.
• [33]Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, et al.: Clinical outcome of patients with major bleeding after venous thromboembolism, Findings from the RIETE Registry. Thromb Haemost 2008, 100:789-796.
• [34]Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SW, Hughes RA, et al.: The impact of long-term warfarin therapy on quality of life Evidence from a randomized trial Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med 1991, 151:1944-1949.
• [35]Gould MK, Dembitzer AD, Sanders GD, Garber AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999, 130:789-799.
• [36]Baglin T, Luddington R, Brown K, Baglin C: Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003, 362:523-526.
• [37]Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al.: Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004, 117:19-25.
• [38]McRae S, Tran H, Schulman S, Ginsberg J, Kearon C: Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006, 368:371-378.
• [39]Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al.: D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006, 355:1780-1789.
• [40]Schulman S, Svenungsson E, Granqvist S: Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998, 104:332-338.
• [41]van den Belt AG, Sanson BJ, Simioni P, Prandoni P, Buller HR, Girolami A, et al.: Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997, 157:2227-2232.
• [42]Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL, et al.: Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008, 100:26-31.
• [43]Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000, 18:3078-3083.
• [44]Monreal M, Falga C, Valdes M, Suarez C, Gabriel F, Tolosa C, et al.: Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006, 4:1950-1956.
• [45]Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al.: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100:3484-3488.
• [46]Trujillo-Santos J, Ruiz-Gamietea A, Luque JM, Samperiz AL, Garcia-Bragado F, Todoli JA, et al.: Predicting recurrences or major bleeding in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res 2009, 123(2):S10-S15.
• [47]Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I, Salloum A, Muralidharan V, et al.: Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004, 125:856-863.
• [48]Trujillo-Santos J, Prandoni P, Rivron-Guillot K, Roman P, Sanchez R, Tiberio G, et al.: Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost 2008, 6:251-255.
• [49]Louzada ML, Majeed H, Wells PS: Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009, 123:837-844.
• [50]Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al.: American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25:5490-5505.
• [51]Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ: III: Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999, 159:445-453.
• [52]Kucher N, Quiroz R, McKean S, Sasahara AA, Goldhaber SZ: Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vasc Med 2005, 10:251-256.
• [53]Camm AJ, Bounameaux H: Edoxaban: a new oral direct factor xa inhibitor. Drugs 2011, 71:1503-1526.
• [54]Clinical Trials Idenfifier NCT00643201: Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism. ClinicalTrials.gov web site; [http://clinicaltrials.gov/ct2/show/NCT00643201?term=00643201&rank=1 webcite] Accessed October 22, 2012
• [55]Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, et al.: Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007, 357:1094-1104.
• [56]Uchino K, Hernandez AV: Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012, 172:397-402.
• [57]Schulman S, Baanstra D, Eriksson H, Goldhaber S, Kakkar A, Kearon C, et al.: Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism. International Society on Thrombosis and Haemostasis; [http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2011.04380_1.x/pdf webcite] Accessed October 22, 2012
• [58]Schulman S, Eriksson H, Goldhaber SZ, Kakkar AK, Kearon C, Kvamme AM, et al.: Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. International Society on Thrombosis and Haemostasis; [http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2011.04380_1.x/pdf webcite] Accessed October 22, 2012
• [59]Eriksson BI, Smith JJ, Caprini J, Hantel S, Clemens A, Feuring M, et al.: Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Thromb Res 2012, 130:396-402.
• [60]Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D: Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 2010, 27:623-633.
• [61]Rose AJ, Berlowitz DR, Ash AS, Ozonoff A, Hylek EM, Goldhaber-Fiebert JD: The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011, 4:416-424.
• [62]Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ: Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011, 32:2282-2289.
• [63]Nichol MB, Knight TK, Dow T, Wygant G, Borok G, Hauch O, et al.: Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother 2008, 42:62-70.
• [64]Meijer K, Kim YK, Carter D, Schulman S: A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery. Thromb Haemost 2011, 105:232-238.
• [65]Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O: Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005, 21:1583-1594.
• [66]Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S: Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006, 37:1075-1080.
• [67]European Medicines Agency: Questions and answers on the review of bleeding risk with Pradaxa (dabigatran etexilate). European Medicines Agency web sitehttp://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/05/WC500127768.pdf webcite] Accessed. November 6, 2012.
• [68]US Food and Drug Administration: FDA drug safety communication: update on the risk for serious bleeding events with the anticoagulant Pradaxa. US Food and Drug Administration web site. 2012. http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm webcite] Accessed November 6, 2012
• [69]Rosencher R, Samama CM, Feuring M, Kleine E, Salmio S, Clemens A, et al.: Safety and efficacy of once daily 220 mg dabigatran etexilate in a real-world noninterventional study of more than 5000 patients after total knee or hip replacement. American Heart Association Scientific Sessions web site, 2012; [http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=2974&sKey=4911efc8-20d6-42ba-a562-4087d52e57e4&cKey=d643dab9-0440-4cf3-b861-caf6542d91bb&mKey=%7b14145D5B-F96B-4354-8237-8F0937744BA4%7d webcite] Accessed November 6, 2012